XML 18 R7.htm IDEA: XBRL DOCUMENT v3.25.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Treasury Stock
Balance at beginning of period (in shares) at Dec. 31, 2023   45,393,260        
Balance at beginning of period at Dec. 31, 2023 $ 549,496 $ 774 $ 677,886 $ 403,923 $ (428) $ (532,659)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income attributable to common stockholders for the period 18,167     18,167    
Foreign currency translation 184       184  
Stock-based compensation (in shares)   334,955        
Stock-based compensation 3,246 $ 6 3,240      
Stock repurchase (in shares)   (589,144)        
Stock repurchases (22,138)         (22,138)
Common stock dividends (3,152)     (3,152)    
Unrealized gain on derivative instruments, net of tax 276       276  
Stock option exercises (in shares)   500        
Stock option exercises 7   7      
Balance at end of period (in shares) at Mar. 31, 2024   45,139,571        
Balance at end of period at Mar. 31, 2024 546,086 $ 780 681,133 418,938 32 (554,797)
Balance at beginning of period (in shares) at Dec. 31, 2023   45,393,260        
Balance at beginning of period at Dec. 31, 2023 549,496 $ 774 677,886 403,923 (428) (532,659)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income attributable to common stockholders for the period (283,041)          
Foreign currency translation (1,795)          
Unrealized gain on derivative instruments, net of tax (902)          
Balance at end of period (in shares) at Sep. 30, 2024   43,336,755        
Balance at end of period at Sep. 30, 2024 200,520 $ 781 687,801 109,995 (3,125) (594,932)
Balance at beginning of period (in shares) at Mar. 31, 2024   45,139,571        
Balance at beginning of period at Mar. 31, 2024 546,086 $ 780 681,133 418,938 32 (554,797)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income attributable to common stockholders for the period 28,958     28,958    
Foreign currency translation (1,192)       (1,192)  
Stock-based compensation (in shares)   21,500        
Stock-based compensation 3,372 $ 1 3,371      
Stock repurchase (in shares)   (935,856)        
Stock repurchases (21,696)         (21,696)
Common stock dividends (4,162)     (4,162)    
Unrealized gain on derivative instruments, net of tax (941)       (941)  
Balance at end of period (in shares) at Jun. 30, 2024   44,225,215        
Balance at end of period at Jun. 30, 2024 550,425 $ 781 684,504 443,734 (2,101) (576,493)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income attributable to common stockholders for the period (330,166)     (330,166)    
Foreign currency translation (787)       (787)  
Stock-based compensation (in shares)   2,419        
Stock-based compensation 3,297   3,297      
Stock repurchase (in shares)   (890,879)        
Stock repurchases (18,439)         (18,439)
Common stock dividends (3,573)     (3,573)    
Unrealized gain on derivative instruments, net of tax (237)       (237)  
Balance at end of period (in shares) at Sep. 30, 2024   43,336,755        
Balance at end of period at Sep. 30, 2024 $ 200,520 $ 781 687,801 109,995 (3,125) (594,932)
Balance at beginning of period (in shares) at Dec. 31, 2024 42,882,308 42,882,308        
Balance at beginning of period at Dec. 31, 2024 $ 188,830 $ 781 689,216 105,633 (3,229) (603,571)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income attributable to common stockholders for the period 230,941     230,941    
Foreign currency translation 167       167  
Stock-based compensation (in shares)   298,701        
Stock-based compensation 3,249 $ 5 3,244      
Stock repurchase (in shares)   (1,033,764)        
Stock repurchases (16,504)         (16,504)
Common stock dividends (3,465)     (3,465)    
Unrealized gain on derivative instruments, net of tax 612       612  
Stock option exercises (in shares)   750        
Stock option exercises 11   11      
Balance at end of period (in shares) at Mar. 31, 2025   42,147,995        
Balance at end of period at Mar. 31, 2025 $ 403,841 $ 786 692,471 333,109 (2,450) (620,075)
Balance at beginning of period (in shares) at Dec. 31, 2024 42,882,308 42,882,308        
Balance at beginning of period at Dec. 31, 2024 $ 188,830 $ 781 689,216 105,633 (3,229) (603,571)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income attributable to common stockholders for the period 261,329          
Foreign currency translation 1,652          
Unrealized gain on derivative instruments, net of tax $ 1,112          
Balance at end of period (in shares) at Sep. 30, 2025 40,516,637 40,516,637        
Balance at end of period at Sep. 30, 2025 $ 418,725 $ 787 698,116 356,964 (465) (636,677)
Balance at beginning of period (in shares) at Mar. 31, 2025   42,147,995        
Balance at beginning of period at Mar. 31, 2025 403,841 $ 786 692,471 333,109 (2,450) (620,075)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income attributable to common stockholders for the period (9,589)     (9,589)    
Foreign currency translation 1,180       1,180  
Stock-based compensation (in shares)   26,868        
Stock-based compensation 2,361 $ 1 2,372     (12)
Stock repurchase (in shares)   (1,085,489)        
Stock repurchases (10,412)         (10,412)
Common stock dividends (3,232)     (3,232)    
Unrealized gain on derivative instruments, net of tax 1,068       1,068  
Balance at end of period (in shares) at Jun. 30, 2025   41,089,374        
Balance at end of period at Jun. 30, 2025 385,217 $ 787 694,843 320,288 (202) (630,499)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income attributable to common stockholders for the period 39,977     39,977    
Foreign currency translation 305       305  
Stock-based compensation (in shares)   2,835        
Stock-based compensation 3,258   3,273     (15)
Stock repurchase (in shares)   (575,572)        
Stock repurchases (6,163)         (6,163)
Common stock dividends (3,301)     (3,301)    
Unrealized gain on derivative instruments, net of tax $ (568)       (568)  
Balance at end of period (in shares) at Sep. 30, 2025 40,516,637 40,516,637        
Balance at end of period at Sep. 30, 2025 $ 418,725 $ 787 $ 698,116 $ 356,964 $ (465) $ (636,677)